A startup biotech company out of King’s College London, Korecyte Bio, is using hypoxia to target solid tumors. It's agreement with CGT Catapult will focus on advancing its 'HypoxiCAR' platform for solid tumors. Read full article here: #kingscollege #CART www.bioprocessintl.com/deal-making/...

CGT Catapult teams with Korecyte Bio on low-oxygen CAR-T platform

A startup biotech company out of King’s College London is using hypoxia to target solid tumors.

bioprocessintl.com

UK’s NICE approves reimbursement of Genmab’s cervical cancer antibody drug. The regulatory body changed its opinion on antibody conjugate therapy Tivdak, paving the way for NHS use. Full article below: #NICE #cervicalcancer www.bioxconomy.com/modalities/u...

UK's NICE approves reimbursement of cervical cancer antibody drug

The regulatory body changed its opinion on antibody conjugate therapy Tivdak, paving way for NHS use.

bioxconomy.com

Antibody developers are seeing regulatory wins and clinical trial successes for several different forms of cancer. From trial successes and approvals, antibodies are achieving better results than thought possible. Read my full article here: #antibodies #cancer www.bioxconomy.com/modalities/a...

Antibody earthquake immunotherapies reach cancer patients

Antibody drug developers are seeing regulatory wins and clinical trial successes for several different forms of cancer.

bioxconomy.com

Capsida confirms the closure of the SYNRGY trial, with the safety of its gene therapy remaining unknown. The clinical trial for the rare disease STXBP1 was originally put on hold following the death of a child. Read my full article here: #clinicaltrial #capsida www.bioxconomy.com/modalities/c...

Capsida confirms closure of SYNRGY gene therapy trial

The clinical trial for the rare disease STXBP1 was originally put on hold following the death of a child.

bioxconomy.com

Americans spend more on healthcare than any other country for worse outcomes. To help reduce the $4.8 trillion spent annually, companies like SHARx are sourcing prescriptions outside of the insurance system. Read my full article here: #drugprices #US www.bioprocessintl.com/bioprocess-i...

Rising drug costs challenge US healthcare system

Americans face soaring drug prices as PBMs inflate costs and rebates drive profits in a complex healthcare market.

bioprocessintl.com

This is such an impressive investigative piece from @milliehoe.bsky.social. It was an honor to get the chance to edit it alongside Josh Abbott. If you haven't given it a read, set aside a few minutes and check it out! Promise it's worth it.

Millie Hoe Science Journalist@milliehoe.bsky.social · 4mo ago

Experimental DIY peptides are taking the US by storm. BioXconomy and BPI investigate the booming underground peptide market - and the dangers it brings with it. Read my full investigative piece below: #peptide #glp #investigation www.bioxconomy.com/modalities/d...

The University of Barcelona is building a not-for-profit manufacturing model to get CAR Ts to patients sooner. Read my full article below: #nonprofit #CART #barcelona www.bioprocessintl.com/therapeutic-...

University of Barcelona tackles CAR-T therapy accessibility

University of Barcelona develops ARI-0001, a not-for-profit CAR-T therapy using EU hospital exemption rules to improve patient access to cancer treatment.

bioprocessintl.com

Large nonprofit The Gates Foundation is focusing on improving global health inequality by investing in biomanufacturing. Read my full article below: #nonprofit #gatesfoundation www.bioprocessintl.com/global-marke...

Gates Foundation invests in manufacturing to increase drug access

The large nonprofit is focusing on improving global health inequality by investing in biomanufacturing.

bioprocessintl.com

CEPI is using AI to achieve its vaccine goal, aiming to develop safe, effective vaccines within 100 days of identifying pandemic threats. Read my full article below: #AI #pandemic www.bioprocessintl.com/therapeutic-...

CEPI’s Pandemic Preparedness engine uses AI to predict outbreaks

CEPI uses AI to achieve its vaccine goal, aiming to develop safe, effective vaccines within 100 days of identifying pandemic threats.

bioprocessintl.com

Experimental DIY peptides are taking the US by storm. BioXconomy and BPI investigate the booming underground peptide market - and the dangers it brings with it. Read my full investigative piece below: #peptide #glp #investigation www.bioxconomy.com/modalities/d...

Experimental injectable peptides craze takes US by storm

BioXconomy and BPI investigate the booming underground peptide market – and the dangers it brings with it.

bioxconomy.com

Lipid nanoparticles have transformed the way biologics are delivered, creating robust and highly specific treatment options across a range of conditions. Read my roundup on LNPs below: #LNPs #mRNA www.bioxconomy.com/modalities/l...

LNP versatility: From scarless healing to pancreatic cancer

Lipid nanoparticles have transformed the way biologics are delivered, creating robust and highly specific treatment options across a range of conditions.

bioxconomy.com

New clinical trial results show promise for a monoclonal antibody immunosuppressant, allowing pancreatic islet transplants in diabetes patients. Read my full article below: #diabetes #transplant #antibodies www.bioxconomy.com/modalities/m...

mAb-based immunosuppressant supports diabetes cell transplants

New clinical trial results show promise for a monoclonal antibody immunosuppressant.

bioxconomy.com

Boehringer Ingelheim are set to partner with OpenProtein.AI The collaboration will focus on the co-development of an AI antibody discovery platform. Read my full article below: #AI #antibody www.bioxconomy.com/modalities/p...

Boehringer Ingelheim partners with OpenProtein.AI

The collaboration will focus on the co-development of an AI antibody discovery platform.

bioxconomy.com

Pharma giant GSK says it has seen positive results from its BEHOLD-1 trial treating ovarian and endometrial cancer. Read my full article below: #gsk #oncology www.bioxconomy.com/modalities/g...

GSK’s ADC succeeds in treating advanced gynecological cancers

The pharma giant says it has seen positive results from its BEHOLD-1 trial treating ovarian and endometrial cancer.

bioxconomy.com

The US Pharmacopeia highlights risks of Red Sea trade disruptions due to the ongoing conflict with Iran, impacting US drug supplies. 73% of flumazenil APIs and 48% of amoxicillin supplies are at risk. Read my full article here: #iran #war #drugshortage www.bioprocessintl.com/global-marke...

USP warns Red Sea blockades may cause US drug shortages

The US Pharmacopeia highlights risks of Red Sea trade disruptions, impacting US drug supplies, with 73% of flumazenil APIs and 48% of amoxicillin at risk.

bioprocessintl.com

The Iran war may incite drug shortages in the US. From the import of key pharmaceutical ingredients to the rising manufacturing costs of medicines, the war is causing far-reaching issues beyond the price of oil. Read my full article below: #iran #pharma www.bioprocessintl.com/global-marke...

Middle East conflict disrupts global pharmaceutical supply chains

Middle East conflict disrupts pharma supply chains, raising costs and risking shortages of key medicines globally.

bioprocessintl.com

Pancreatic cancer is a devastating disease, with high mortality rates due to late symptom onset. Scientists speculate immune evasion is the reason for its late discovery. A new mRNA therapy from UPenn offers a solution. Read my full article here: #cancer #mRNA www.bioxconomy.com/modalities/c...

mRNA therapy thwarts pancreatic tumor immune evasion

mRNA delivered in vivo by antibody-targeted LNPs disrupts the defenses and microenvironment of pancreatic tumors.

bioxconomy.com

Earlier this month, US President Donald Trump signed into effect a series of trade tariffs to hit the pharmaceutical and biotech industry. Read my full article below: #trump #pharma #tariffs www.bioprocessintl.com/regulations/...

Trump imposes tariffs on pharma to boost US drug manufacturing

President Trump enacts tariffs on imported drugs to strengthen US manufacturing, sparking industry concerns over costs, supply chains, and patient access.

bioprocessintl.com

Up to 30% of women with endometriosis experience fertility problems, and current cytokine-based treatments come with risks. A new mRNA therapy out of John Hopkins has shown promising preclinical results. Read my full article below: #endometriosis #fertility #mRNA www.bioxconomy.com/modalities/i...

Improving parenthood chances with endometrium-targeted mRNA

Peptide-directed mRNA-LNP could treat reproductive disorders by thickening the uterine lining.

bioxconomy.com

Lonza announced it has inked a deal with ImmuneOncia to produce a monoclonal antibody (mAb) therapy. The treatment will target refractory NK/T-cell lymphoma, a rare form of blood cancer. Read my full article below: #lymphoma #blood #antibody www.bioprocessintl.com/deal-making/...

Lonza to manufacture ImmuneOncia’s antibody for lymphoma

Lonza partners with ImmuneOncia to manufacture Danburstotug, a promising mAb therapy for rare NK/T-cell lymphoma, advancing to Phase III trials.

bioprocessintl.com

For years, mental health professionals have observed an association between poor diet and severe depression. A new food-derived peptide could take advantage of this gut-brain connection. Read my full article below: #depression #diet #mentalhealth www.bioxconomy.com/modalities/y...

Using a food-derived peptide to treat depression, dementia

Researchers from Kyoto, Japan, are advancing a drug that modulates the gut-brain axis with pro-cognitive effects across a range of indications.

bioxconomy.com

Pfizer recently announced promising Phase II clinical trial results (NCT05995964) for its trispecific antibody product, tilrekimig, targeting eczema and other inflammatory conditions. Read my full article below: #eczema #antibody #pfizer www.bioxconomy.com/modalities/p...

Pfizer's trispecific antibody shows promise against eczema

The pharmaceutical giant announced its candidate, tilrekimig, significantly reduced eczema severity in clinical trials.

bioxconomy.com

What happens to gene therapies that are proven to save lives, but that are not commercially viable? Academic institutions are picking up the slack in a for-profit industry. Read my full article below: #genetherapy #access #nonprofit www.bioprocessintl.com/upstream-dow...

Academic institutions tackle gene therapy costs and accessibility

Academics innovate gene therapy manufacturing to cut costs and improve access, addressing commercialization challenges and saving lives worldwide

bioprocessintl.com

The FDA asked pharma company UniQure for a “double-blind, sham surgery-controlled study” of its mutation-rescuing Huntington’s disease therapy. Study leader Edward Wild has expressed ethical concerns. Read my full article below: #FDA #Huntington #genetherapy www.bioxconomy.com/modalities/f...

FDA demands sham arm for Huntington’s gene therapy

The US agency’s U-turn would postpone treatment for participants in the placebo group.

bioxconomy.com

Researchers from Columbia University were able to up-regulate a cardio-protective peptide in animal models using self-amplifying RNA. The peptide preserves cardiac function after a heart attack. Read my full article below: #heart #peptide #heartattack www.bioxconomy.com/modalities/h...

RNA-delivered peptide boosts recovery after heart attack

A self-amplifying RNA with a “smart drug activation system” provides heart tissue-specific regeneration.

bioxconomy.com

CDMO Neuland Laboratories announced that it will open its peptide facility in summer 2026. The site, which will produce glucagon-like peptide-1 (GLP-1s), is just 40 miles from Hyderabad, India. Read my full article below: #peptide #GLP www.bioxconomy.com/modalities/n...

Neuland announces plans for Hyderabad GLP-1 CMC facility

Located in the village of Bonthapally, the peptide CMC site is set to open summer 2026.

bioxconomy.com

‘Quieting craving itself’: GLP-1s reduce risk of substance addiction in US veterans In a landmark observational study of over 600,000 US veterans with type-2 diabetes, #GLPs reduced addiction rates and adverse outcomes. Read my full article below: #news #science www.bioxconomy.com/modalities/q...

GLP-1s reduce risk of substance addiction in US veterans

A study of over 600,000 veterans suggests GLP-1s reduce the chances of developing addiction while improving outcomes for those already addicted.

bioxconomy.com

The South African government and Gilead Sciences enter discussions for local manufacturing of #HIV preventative drug, lenacapavir. The initiative is part of a scheme with Unitaid to increase equitable access in endemic areas. Read my full article below: #news www.bioprocessintl.com/bioprocess-i...

South Africa negotiate with Gilead for HIV drug

Gilead’s investigational drug lenacapavir provides protection against infection.

bioprocessintl.com

Peptides market to explode following success of GLP-1s. Experts predict a value of almost $300 billion by 2033, with the US dominating more than 60% of the market. #news #invest #glps Read my full article below: www.bioxconomy.com/modalities/p...

Peptide therapeutics market set to soar

The US is driving innovation in the peptide therapeutics space, especially around GLP-1s.

bioxconomy.com

Merck make 150+ redundancies as HPV vaccine sales plummet. The company announced layoffs at its Durham, North Carolina facilities as Gardasil sales fail to meet expectations. Read my full article below: #news #merck #vaccine www.bioprocessintl.com/global-marke...

Merck identifies redundancies in NC as vaccine sales plummet

The company announced layoffs at its Durham facilities as Gardasil sales fail to meet expectations.

bioprocessintl.com